查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081459

肺癌治療市場：2026-2032年全球市場預測（依療法分類、癌症類型、分子類型、給藥途徑、產品類型、最終用戶和分銷管道分類）

Lung Cancer Drugs Market by Therapeutic Class, Cancer Type, Molecule Type, Route Of Administration, Product Category, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺癌治療市場將成長至 554.3 億美元，複合年成長率為 9.20%。

主要市場統計數據
基準年 2025 299.1億美元
預計年份：2026年 326.1億美元
預測年份 2032 554.3億美元
複合年成長率 (%) 9.20%

肺癌仍然是全球癌症死亡的首要原因，因此肺癌治療在腫瘤學創新中發揮核心作用。根據國際癌症研究機構（IARC）發布的《2022年全球肺癌研究報告》（GLOBOCAN 2022），全球預計將新增250萬例肺癌病例，並有180萬人死於肺癌。這凸顯了儘管早期診斷、控煙和擴大篩檢項目方面取得了進展，但仍存在許多未被滿足的需求。

肺癌治療格局正日益受到精準腫瘤學、免疫療法、抗體藥物複合體（ADC）、定向小分子藥物以及基於生物標記的治療順序的影響。雖然非小細胞肺癌佔診斷總數的絕大多數，並且是臨床研發的核心，但小細胞肺癌仍然是治療需求龐大的領域。取得進展需要證實總生存期（OS）的延長、可靠的伴隨診斷、公平的醫療資源獲取以及支持基於價值的腫瘤治療決策的真實世界數據。

肺癌治療趨勢的變革性變化

肺癌治療格局正從廣譜化療轉向分子標靶治療。目前，EGFR、ALK、ROS1、BRAF、MET 14號外顯子、RET、NTRK、HER2、KRAS G12C 和 PD-L1 的檢測結果正在影響治療方案的選擇，並且在已批准的適應症和臨床指南的支持下，幫助臨床醫生為患者匹配合適的標靶治療和免疫查核點抑制劑。

人工智慧（AI）的累積影響

人工智慧（AI）正在影響肺癌治療的各個層面，從藥物研發和臨床試驗設計到診斷和商業策略。人工智慧驅動的影像分析正在輔助結節檢測和放射診斷工作流程，而計算生物學則有助於識別藥物標靶、抗藥性機制以及可能受益於特定療法的患者亞群。

關鍵區域洞察

亞太地區是肺癌治療的主要需求中心，這主要歸因於該地區肺癌疾病負擔沉重、患者群體龐大，以及中國、日本、韓國、印度、澳洲和東協等市場不斷完善的癌症醫療基礎設施。在中國，癌症藥物核准體係正在加速完善，EGFR抑制劑、PD-1/PD-L1抑制劑和抗體藥物複合體（ADC）等藥物的研發正在蓬勃發展。同時，日本和韓國在精準醫療、基因組檢測和臨床開發方面持續保持主導地位。澳洲已建立起以指南為基礎的醫療保健體系和高品質的癌症登記系統，而印度和東南亞市場對價格合理的標靶治療、免疫療法和分子診斷的需求日益成長。

該小組的主要發現

在東協市場，肺癌治療能力正透過醫院的公私合營、病理網路的擴展以及標靶治療和免疫療法的逐步引入而不斷提升。然而，新加坡、泰國、馬來西亞、印尼、越南和菲律賓的治療可及性仍然參差不齊，因此，定價策略、診斷夥伴關係、臨床醫生培訓以及本地循證醫學證據對於促進基於生物標記的肺癌治療的廣泛應用至關重要。

主要國家的概況

美國是肺癌治療創新和商業化的重要中心，這得益於FDA的腫瘤學審查流程、聯邦醫療保險和私人保險的覆蓋範圍、先進的分子診斷技術以及高密度的臨床試驗。加拿大提供全面的專科癌症護理和省級腫瘤項目，但保險報銷時間和處方藥納入標準因省份而異。墨西哥和巴西是拉丁美洲的主要市場，公共醫療體系、私人腫瘤網路、專科醫生資源和診斷基礎設施的完善，正在推動標靶治療治療和免疫療法的應用。

為行業領導者提供的實用建議

產業領導者應優先考慮以生物標記主導的策略，將藥物研發與檢驗的伴隨診斷、病理工作流程支援以及臨床醫生教育相結合。能夠縮短從切片檢查到治療決策時間的機構可以改善臨床療效，增強治療信心，並促進精準肺癌療法的應用。

調查方法

本執行摘要基於對公開可查來源的三角分析，包括國際癌症研究機構 (IARC) GLOBOCAN 2022 年癌症統計數據、世界衛生組織 (WHO) 癌症負擔參考資料、美國食品藥品監督管理局 (FDA) 和歐洲藥品管理局 (EMA) 癌症藥物批准資訊、關鍵臨床檢驗資訊來源、同行檢驗的腫瘤學文獻以及公開的衛生技術評估 (HTA) 實踐。

結論

隨著精準腫瘤學、免疫療法和基於生物標記的療法不斷革新肺癌治療標準，肺癌治療領域正在迅速發展。持續進步取決於那些能帶來具有臨床意義的生存獲益、克服抗藥性、提高耐受性並能在疾病早期階段惠及患者的療法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肺癌治療市場：依治療分類

  • 化療
  • 聯合治療
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 標靶治療
    • ALK抑制劑
    • EGFR抑制劑
    • ROS1抑制劑

第8章 肺癌治療市場：依癌症類型分類

  • 非小細胞肺癌
  • 小細胞肺癌

第9章 肺癌治療藥物市場：依分子類型分類

  • 單株抗體
  • 小分子藥物

第10章 肺癌治療藥物市場：依給藥途徑分類

  • 口服
  • 腸外

第11章 肺癌治療市場：依產品類型

  • 品牌
  • 非專利的

第12章 肺癌治療藥物市場：依最終用戶分類

  • 居家照護環境
  • 醫院
  • 專科診所

第13章 肺癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 肺癌治療藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 肺癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肺癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited
  • Menarini Group
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zai Lab Limited
Product Code: MRR-434CCDA05288

The Lung Cancer Drugs Market is projected to grow by USD 55.43 billion at a CAGR of 9.20% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.91 billion
Estimated Year [2026] USD 32.61 billion
Forecast Year [2032] USD 55.43 billion
CAGR (%) 9.20%

Lung cancer drugs are central to oncology innovation because lung cancer remains the world's leading cause of cancer death. IARC's GLOBOCAN 2022 estimates about 2.5 million new lung cancer cases and 1.8 million deaths worldwide, underscoring persistent unmet need despite earlier diagnosis, tobacco-control progress, and expanding screening programs.

The lung cancer drugs landscape is increasingly shaped by precision oncology, immunotherapy, antibody-drug conjugates, targeted small molecules, and biomarker-led treatment sequencing. Non-small cell lung cancer accounts for most diagnoses and dominates clinical development, while small cell lung cancer remains an area of high therapeutic need. Progress depends on proven overall survival benefit, reliable companion diagnostics, equitable access, and real-world evidence that supports value-based oncology decisions.

Transformative Shifts in the Lung Cancer Drug Landscape

The lung cancer treatment landscape has shifted from broad chemotherapy toward molecularly defined care. EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK, HER2, KRAS G12C, and PD-L1 testing now influence treatment selection, helping clinicians match patients with targeted therapies or immune checkpoint inhibitors when supported by approved indications and clinical guidelines.

Competition is moving toward next-generation resistance management, earlier-line therapy, perioperative immunotherapy, and combination regimens. Drug developers are also prioritizing brain metastasis activity, improved safety, and oral convenience. Payers and health systems are demanding stronger comparative evidence, while regulators continue to emphasize confirmatory trials, post-marketing safety, and validated diagnostics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is influencing lung cancer drugs across discovery, trial design, diagnosis, and commercial strategy. AI-enabled image analysis supports nodule detection and radiology workflow, while computational biology helps identify drug targets, resistance mechanisms, and patient subgroups that may benefit from specific regimens.

The cumulative impact is operational as well as scientific. Sponsors use machine learning to improve site selection, protocol feasibility, safety-signal detection, and real-world evidence generation. Adoption must remain governed by clinical validation, data quality, bias monitoring, privacy safeguards, and transparent regulatory documentation, particularly when AI outputs affect patient selection or treatment decisions.

Key Regional Insights

Asia-Pacific is a major demand center for lung cancer drugs because of high disease burden, large patient populations, and expanding oncology infrastructure in China, Japan, South Korea, India, Australia, and ASEAN markets. China has accelerated oncology review mechanisms and strong domestic innovation in EGFR inhibitors, PD-1/PD-L1 agents, and antibody-drug conjugate programs, while Japan and South Korea remain leaders in precision medicine adoption, genomic testing, and clinical development. Australia supports guideline-based care and high-quality cancer registries, while India and Southeast Asian markets show rising need for affordable targeted therapy, immunotherapy, and molecular diagnostics.

North America continues to set the pace for premium oncology launches, with the United States supported by FDA oncology pathways, broad biomarker testing, guideline influence, and extensive clinical trial activity. Canada benefits from advanced cancer centers and public reimbursement review, although provincial coverage variability can affect access timing. Europe shows strong evidence-based adoption through EMA review, health technology assessment, and national reimbursement negotiation across the European Union, United Kingdom, Germany, France, Italy, and Spain, with treatment decisions closely tied to demonstrated survival benefit, quality-of-life outcomes, and cost-effectiveness.

Latin America, the Middle East, and Africa present growth opportunities but face uneven access to molecular testing, specialist care, and high-cost immuno-oncology drugs. Brazil and Mexico anchor Latin American demand through a mix of public systems and private oncology networks. Middle Eastern markets, especially GCC countries, are investing in cancer centers, national screening strategies, and specialist capacity. African markets require stronger early diagnosis, pathology infrastructure, supply-chain resilience, oncology workforce development, and affordability programs to improve access to evidence-based lung cancer treatment.

Key Group Insights

ASEAN markets are expanding lung cancer treatment capacity through public-private hospital investment, broader pathology networks, and gradual adoption of targeted therapy and immunotherapy. Access remains mixed across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, making pricing strategy, diagnostics partnerships, clinician education, and local evidence essential for improving uptake of biomarker-driven lung cancer drugs.

The GCC is increasingly important for premium oncology therapies as Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman invest in cancer centers, national health transformation programs, and specialist oncology services. The European Union provides a sophisticated but fragmented reimbursement environment, where centralized regulatory review is only the first step before country-level health technology assessment determines adoption speed, patient eligibility, and pricing conditions.

BRICS countries combine high patient volume with diverse regulatory and affordability conditions, especially across China, India, Brazil, Russia, and South Africa. These markets require localized access models, broader diagnostic capacity, and evidence aligned with public-sector decision-making. G7 markets remain central to launch sequencing, clinical evidence generation, and pricing benchmarks because of advanced oncology infrastructure and mature reimbursement systems. NATO countries overlap significantly with high-income oncology systems, but procurement resilience, medicine supply security, and cross-border clinical research capacity increasingly influence strategic planning.

Key Country Insights

The United States is a leading innovation and commercialization hub for lung cancer drugs, supported by FDA oncology pathways, Medicare and commercial coverage, advanced molecular diagnostics, and high clinical trial density. Canada offers strong specialty cancer care and provincial oncology programs, but reimbursement timing and formulary decisions vary by province. Mexico and Brazil are key Latin American markets where public-sector access, private oncology networks, specialist availability, and diagnostic infrastructure determine uptake of targeted therapy and immunotherapy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain use structured health technology assessment and national reimbursement processes to evaluate overall survival, progression-free survival, quality of life, and budget impact. Germany often provides early post-approval access under AMNOG assessment, while the United Kingdom relies on NICE value assessment to guide reimbursement. France, Italy, and Spain emphasize therapeutic added value and negotiated access, while Russia maintains meaningful oncology demand but faces regulatory, geopolitical, reimbursement, and supply-chain complexity.

China is a high-growth lung cancer drugs market with strong domestic oncology development and expanding access to targeted and immunotherapy agents through national reimbursement negotiations. India has high unmet need and growing private oncology care, but affordability, diagnostic availability, and geographic disparities remain critical. Japan, South Korea, and Australia combine advanced diagnostics, guideline-driven care, organized reimbursement pathways, and high-quality clinical research, making them important countries for evidence generation, biomarker adoption, and premium therapy access.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led strategies that integrate drug development with validated companion diagnostics, pathology workflow support, and clinician education. Organizations that reduce time from biopsy to treatment decision can strengthen clinical outcomes, treatment confidence, and adoption of precision lung cancer drugs.

Developers should invest in resistance-targeting assets, rational combinations, antibody-drug conjugates, and earlier-stage disease indications where survival gains can be clinically meaningful. Commercial teams should align launch plans with payer evidence requirements, including overall survival, progression-free survival, quality-of-life data, safety, comparative effectiveness, and real-world outcomes. Access programs, tiered pricing, patient support, and local partnerships are critical in emerging markets where testing capacity and affordability remain barriers.

Research Methodology

This executive summary is based on triangulation of public, verifiable sources, including IARC GLOBOCAN 2022 cancer statistics, World Health Organization cancer burden references, FDA and EMA oncology approval information, major clinical guideline frameworks, peer-reviewed oncology literature, and publicly available health technology assessment practices.

The analysis emphasizes validated disease burden, regulatory trends, therapy-class evolution, regional access conditions, and observable adoption drivers. Insights were synthesized using market-structure assessment, treatment pathway mapping, regulatory review, and comparative regional analysis. No unsupported market-size figures, market-share claims, or unverified forecasts are used.

Conclusion

The lung cancer drugs landscape is advancing rapidly as precision oncology, immunotherapy, and biomarker-enabled treatment reshape standards of care. Sustained progress will depend on therapies that demonstrate clinically meaningful survival benefit, manage resistance, improve tolerability, and address patients earlier in the disease pathway.

The next phase of competition will reward organizations that combine scientific differentiation with diagnostic access, payer-ready evidence, AI-enabled development efficiency, and region-specific commercialization models. Stakeholders that align innovation with affordability, supply reliability, and real-world outcomes will be best positioned to improve lung cancer care globally.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Lung Cancer Drugs Market, by Therapeutic Class

  • 7.1. Chemotherapy
  • 7.2. Combination Therapy
  • 7.3. Immunotherapy
    • 7.3.1. Ctla-4 Inhibitors
    • 7.3.2. Pd-1 Inhibitors
    • 7.3.3. Pd-L1 Inhibitors
  • 7.4. Targeted Therapy
    • 7.4.1. Alk Inhibitors
    • 7.4.2. EgfR Inhibitors
    • 7.4.3. Ros1 Inhibitors

8. Lung Cancer Drugs Market, by Cancer Type

  • 8.1. Non Small Cell Lung Cancer
  • 8.2. Small Cell Lung Cancer

9. Lung Cancer Drugs Market, by Molecule Type

  • 9.1. Monoclonal Antibodies
  • 9.2. Small Molecule Drugs

10. Lung Cancer Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Lung Cancer Drugs Market, by Product Category

  • 11.1. Branded
  • 11.2. Generic

12. Lung Cancer Drugs Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Lung Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Lung Cancer Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Lung Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Lung Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Amgen Inc.
  • 18.3. Astellas Pharma Inc.
  • 18.4. AstraZeneca PLC
  • 18.5. Bayer AG
  • 18.6. BeiGene, Ltd.
  • 18.7. Blueprint Medicines Corporation
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Daiichi Sankyo Company, Limited
  • 18.11. Eisai Co., Ltd.
  • 18.12. Eli Lilly and Company
  • 18.13. Exelixis, Inc.
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Gilead Sciences, Inc.
  • 18.16. GlaxoSmithKline plc
  • 18.17. Incyte Corporation
  • 18.18. Innovent Biologics, Inc.
  • 18.19. Johnson & Johnson
  • 18.20. Kyowa Kirin Co., Ltd.
  • 18.21. Lupin Limited
  • 18.22. Menarini Group
  • 18.23. Merck & Co., Inc.
  • 18.24. Novartis AG
  • 18.25. Ono Pharmaceutical Co., Ltd.
  • 18.26. Pfizer Inc.
  • 18.27. Roche Holding AG
  • 18.28. Sanofi S.A.
  • 18.29. Sun Pharmaceutical Industries Limited
  • 18.30. Takeda Pharmaceutical Company Limited
  • 18.31. Teva Pharmaceutical Industries Ltd.
  • 18.32. Viatris Inc.
  • 18.33. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LUNG CANCER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LUNG CANCER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LUNG CANCER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. NATO LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. NATO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)